Connect with us

Plato Vertical Search

Fintech

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million

TAMPA, Fla.–(BUSINESS WIRE)–$AMEX #ADDFAlzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the closing of its initial public offering of 2,500,000 shares of its common stock and full exercise of the underwriter’s over-allotment option to purchase 375,000 additional shares of common stock at a price to the public of $5.00 per share. The gross proceeds from the offering to Alzamend, before deducting the underwriting discounts and estimated offering expenses, were approximately $14.4 million. Alzamend’s common stock is listed on The Nasdaq Capital Market under the ticker symbol “ALZN”.

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million

Spartan Capital Securities, LLC acted as the sole book-running manager for the public offering.

The offering was made only by means of a prospectus. Copies of the final prospectus are available on the Securities and Exchange Commission’s website at www.sec.gov and may be obtained from: Spartan Capital Securities, LLC, Attn.: Prospectus Department, 45 Broadway, 19th Floor, New York, NY 10006, by telephone at (212) 293-0123 or by email at [email protected].

The securities described above were offered by Alzamend pursuant to a registration statement on Form S-1 (File No. 333-255955) declared effective by the SEC on June 14, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Olshan Frome Wolosky LLP served as counsel to Alzamend Neuro and Haynes & Boone LLP represented the underwriter.

About Alzamend Neuro

We are a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s Disease (“AD”). With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat AD. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million

Contacts

Email: [email protected] or call: 1-844-722-6333

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.fintechnews.org/alzamend-neuro-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-over-allotment-option-for-gross-proceeds-of-14-4-million/

Advertisement. Scroll to continue reading.
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
Advertisement Buy Bitcoin at coinsmart.com
Advertisement
Advertisement

Related Streams

Big Data

This article was published as a part of the Data Science Blogathon. Computer Vision has opened up a plethora of possibilities and one of the...

Big Data

Data is one of the most important tools brands and retailers can use to effectively meet the needs of their customers. However, privacy concerns...

Big Data

When the pandemic struck, it caused us to leave our offices, work from home, and rush to the cloud. Centralized offices became decentralized networks of...

Fintech

UK bank will look to utilise nCino's end-to-end cloud-based platform.